The governments world over are realizing the cost cutting benefits of biosimilars, which when introduced at a discounted price, entice competition and reduce the overall cost of the therapy. For Example, to further increase prescriber’s confidence and encourage the use of biosimilars, the EMA has planned to introduce risk management plans. In another country America, currently devoid of a specific regulatory pathway, all is set to change in 2014 when the country’s new framework for biosimilars, set out by The Patient Protection and Affordable Care Act of March 2010, will come into effect. Coming to the South Korean pharmaceutical industry, a remarkable feature is the government’s initiative and involvement in the entire lifecycle of biosimilars. In addition to setting a target global share of 22% by 2020, the South Korean government has also engaged in creating a robust platform to provide infrastructure and financial assistance.